ZAI Lab In-licenses Potential Liver Cancer Drug from BMS

ZAI Lab of Shanghai has in-licensed China rights to a liver cancer drug candidate from Bristol-Myers Squibb. Brivanib is an oral kinase inhibitor that is in Phase III trials for oncology indications including hepatocellular carcinoma, which is especially prevalent in China. ZAI Lab will be responsible for developing, manufacturing and commercializing brivanib in China, though BMS will have an option to co-promote the drug. ZAI will pay BMS development milestones and tiered royalties if brivanib is approved in China. More details.... Stock Symbol: (NYSE: BMY) Share this with colleagues: // //